As one of the main R&D facilities of AstraZeneca, Innovation Center China (ICC) opened its lab vacilities in Zhangjiang Hi-tech Park in October 2007. ICC’s presence is traced back to the announcement in May 2006 as part of a large $100 million R&D investement in China.
With an emphasis on “innovation,” ICC is focused on the benefit and value of innovative medicines for Chinese Patients. The initial concentration is on cancer through the development of knowledge about Chinese patients, biomarkers and genetics. Researchers at the facility work on the identification, development and validation of new biomarkers. The centre also draws on the extensive alternative compound resources of AstraZeneca to analyse and select suitable drugs for Chinese patients, these also provide useful data for further decision-making in clinical trials.
